Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401723 | 0.84 | HDAC4 (0.33) | RAB9ASMN1; SMN2GAACTSLCTSB | |
| SCHEMBL16313237 | 0.81 | RAB9A (0.40) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL13338252 | 0.81 | SMN1; SMN2 (0.38) | RAB9ASMN1; SMN2GAACAPN1NPC1 | |
| SCHEMBL16328219 | 0.81 | SMN1; SMN2 (0.38) | RAB9ASMN1; SMN2GAACAPN1NPC1 | |
| SCHEMBL16330212 | 0.80 | — | — | |
| SCHEMBL15219795 | 0.78 | RAB9A (0.33) | RAB9ASMN1; SMN2GAANPC1MAPT | |
| SCHEMBL15368937 | 0.78 | RAB9A (0.36) | RAB9ASMN1; SMN2GAACAPN1NPC1 | |
| SCHEMBL16328624 | 0.77 | L3MBTL1 (0.39) | RAB9ASMN1; SMN2GAACAPN1NPC1 | |
| SCHEMBL15368934 | 0.77 | PKM (0.38) | RAB9ASMN1; SMN2GAACAPN1 | |
| SCHEMBL14943216 | 0.75 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2GAANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | RAB9A 2004/4885SMN1; SMN2 2265/4885GAA 773/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | RAB9A 2004/4885SMN1; SMN2 2265/4885GAA 773/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | RAB9A 3172/4885SMN1; SMN2 2646/4885GAA 751/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | RAB9A 2014/4885SMN1; SMN2 2156/4885GAA 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.